The historical rank and industry rank for Barinthus Biotherapeutics's Net Margin % or its related term are showing as below:
BRNS's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -88.815 * Ranked among companies with meaningful Net Margin % only.
Barinthus Biotherapeutics (NAS:BRNS) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Barinthus Biotherapeutics Net Margin % Related Terms
Barinthus Biotherapeutics Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Barinthus Biotherapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Barinthus Biotherapeutics Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Barinthus Biotherapeutics's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Barinthus Biotherapeutics (BRNS) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Barinthus Biotherapeutics and its competitors. According to the industry distribution chart, Barinthus Biotherapeutics ranks #999999 out of 946 companies in the Biotechnology industry.
Is Barinthus Biotherapeutics' Net Margin % too high?
Barinthus Biotherapeutics' current Net Margin % is 0.00%. Based on the distribution chart, Barinthus Biotherapeutics ranks #999999 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Barinthus Biotherapeutics has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' Net Margin % compare to KYNB and SER?
According to the Biotechnology industry distribution chart, Barinthus Biotherapeutics ranks #999999 out of 946 companies for Net Margin %. This places Barinthus Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Barinthus Biotherapeutics and its competitors. Barinthus Biotherapeutics's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Barinthus Biotherapeutics (BRNS) is currently considered Possible Value Trap. The stock's GF Value™ is $1.12, compared to a current price of $0.70 — trading 37.5% below its estimated fair value. The current Net Margin % is 0.00%. Barinthus Biotherapeutics' overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Barinthus Biotherapeutics (BRNS), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Barinthus Biotherapeutics (BRNS) Overvalued in 2026?
Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued.
The current stock price of $0.70 is trading 37.5% below its estimated GF Value™ of $1.12.
GuruFocus considers Barinthus Biotherapeutics to be Possible Value Trap.
Key valuation signals for BRNS:
Net Margin %: 0.00%
GF Value™: $1.12 vs. price of $0.70 (37.5% below fair value)
No single metric tells the full story. See the BRNS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
52GF Score
Get the complete analysis for BRNS
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BRNS has been successfully added to your 
